The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...

Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of ...

Population-based analyses of new vaccination programmes provide robust real-world evidence for post-licensure vaccine ...

The risk for new-onset or recurrent AF was not increased among older adult patients with preexisting conditions following RSV vaccination.

Australian medicines regulator, the Therapeutic Goods Administration (TGA), has granted approval for mRESVIA (mRNA-1345), an ...

The authors assessed the patient characteristics associated with RSV vaccination among older adults hospitalized during the ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods ...